Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.

Karimi MA, Gholami Chahkand MS, Dadkhah PA, Sheikhzadeh F, Yaghoubi S, Esmaeilpour Moallem F, Deyhimi MS, Arab Bafrani M, Shahrokhi M, Nasrollahizadeh A

Frontiers in pharmacology15 May 2025Cited by 11 (Europe PMC)

PMID40444045PMCIDPMC12120964DOI10.3389/fphar.2025.1438318PepBankPUB-40444045

Download PDF PubMedAsk about this study

Jump to 26 results

Summary

BackgroundThis study seeks to compare the effectiveness of Semaglutide compared to Liraglutide, Dulaglutide, or Tirzepatide. Additionally, it aims to investigate the implications of transitioning from Dulaglutide or Liraglutide to Semaglutide.MethodsWe searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials. Analyses were conducted using Review Manager (RevMan) version 5.4.1 and STATA 17.ResultsThe meta-analysis comprised 16 studies and 5,997 patients. Semaglutide significantly reduced hemoglobin A1c (HbA1c) levels compared to Liraglutide (0.56; 95% CI: 0.19-0.94; p < 0.001). However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change. In comparison to Dulaglutide, Semaglutide displayed superior efficacy in reducing HbA1c levels (3.72; 95% CI: 0.02-7.41; p = 0.05) and FBS (2.66; 95% CI: 0.26-5.07; p = 0.03). However, no significant differences were found in weight and BMI change. Tirzepatide exhibited a notable advantage over Semaglutide in reducing HbA1c levels (-0.45; 95% CI: -0.88 to -0.02; p = 0.04). However, no clear superiority was observed for weight and FBS change. Transitions from Liraglutide to Semaglutide did not significantly impact HbA1c levels. However, weight loss (2.48; 95% CI: 0.45-4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55-20; p = 0.04) were observed. Transitioning from Dulaglutide to Semaglutide did not significantly affect HbA1c levels and weight change.ConclusionWhile the precise source of heterogeneity remains elusive across most studies, analyses consistently demonstrate Semaglutide's superior efficacy compared to Liraglutide in reducing both HbA1c levels and weight. Moreover, it presents advantages over Dulaglutide, specifically in lowering FBS levels. However, Tirzepatide surpasses Semaglutide in its efficacy for reducing HbA1c levels.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study26

18 results from studies that gave the peptide. 18 results from people.

01HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide significantly reduced HbA1c compared with liraglutide (printed comparative estimate 0.56,95% CI 0.19 to0.94;P<0.001); effect type/units were unstated and numbers retain the published semaglutide versus liraglutide orientation.
In plain wordsIn reviewed clinical studies, semaglutide significantly lowered HbA1c compared with liraglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Printed comparative estimate
0.56
Semaglutide versus liraglutide; effect type/units unstated, not inverted
95% CI
0.19 to 0.94
published Semaglutide versus liraglutide orientation
P-value
< 0.001
published Semaglutide versus liraglutide comparison
Source sentences
Summary
Semaglutide significantly reduced hemoglobin A1c (HbA1c) levels compared to Liraglutide (0.56; 95% CI: 0.19-0.94; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404501
02HumanSystematic reviewEfficacy outcome
Across included clinical studies, liraglutide had a smaller HbA1c reduction than semaglutide (printed comparative estimate 0.56,95% CI 0.19 to0.94;P<0.001); effect type/units were unstated and numbers retain the published semaglutide versus liraglutide orientation.
In plain wordsIn reviewed clinical studies, liraglutide had a smaller HbA1c reduction than semaglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c-reduction magnitude
Study
n: not reported in source
Comparator
semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Printed comparative estimate
0.56
Semaglutide versus liraglutide; effect type/units unstated, not inverted
95% CI
0.19 to 0.94
published Semaglutide versus liraglutide orientation
P-value
< 0.001
published Semaglutide versus liraglutide comparison
Source sentences
Summary
Semaglutide significantly reduced hemoglobin A1c (HbA1c) levels compared to Liraglutide (0.56; 95% CI: 0.19-0.94; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404502
03HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide and liraglutide had no significant difference in fasting blood sugar.
In plain wordsIn reviewed clinical studies, semaglutide and liraglutide had no significant difference in fasting blood sugar.
Peptide
Semaglutide
Outcome
No significant changeFasting blood sugar
Study
n: not reported in source
Comparator
liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404503
04HumanSystematic reviewEfficacy outcome
Across included clinical studies, liraglutide and semaglutide had no significant difference in fasting blood sugar.
In plain wordsIn reviewed clinical studies, liraglutide and semaglutide had no significant difference in fasting blood sugar.
Peptide
Liraglutide
Outcome
No significant changeFasting blood sugar
Study
n: not reported in source
Comparator
semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404504
05HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide and liraglutide had no significant difference in body mass index.
In plain wordsIn reviewed clinical studies, semaglutide and liraglutide had no significant difference in body mass index.
Peptide
Semaglutide
Outcome
No significant changeBody mass index
Study
n: not reported in source
Comparator
liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404505
06HumanSystematic reviewEfficacy outcome
Across included clinical studies, liraglutide and semaglutide had no significant difference in body mass index.
In plain wordsIn reviewed clinical studies, liraglutide and semaglutide had no significant difference in body mass index.
Peptide
Liraglutide
Outcome
No significant changeBody mass index
Study
n: not reported in source
Comparator
semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404506
07HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide and liraglutide had no significant difference in weight change.
In plain wordsIn reviewed clinical studies, semaglutide and liraglutide had no significant difference in weight change.
Peptide
Semaglutide
Outcome
No significant changeWeight change
Study
n: not reported in source
Comparator
liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404507
08HumanSystematic reviewEfficacy outcome
Across included clinical studies, liraglutide and semaglutide had no significant difference in weight change.
In plain wordsIn reviewed clinical studies, liraglutide and semaglutide had no significant difference in weight change.
Peptide
Liraglutide
Outcome
No significant changeWeight change
Study
n: not reported in source
Comparator
semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no significant differences were observed between Semaglutide and Liraglutide in terms of fasting blood sugar (FBS), body mass index (BMI), and weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404508
09HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide showed superior efficacy to dulaglutide in reducing HbA1c (printed comparative estimate 3.72,95% CI 0.02 to7.41;P=0.050); effect type/units were unstated and numbers retain the published semaglutide versus dulaglutide orientation.
In plain wordsIn reviewed clinical studies, semaglutide lowered HbA1c more than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Printed comparative estimate
3.72
Semaglutide versus dulaglutide; effect type/units unstated, not inverted
95% CI
0.02 to 7.41
published Semaglutide versus dulaglutide orientation
P-value
0.05
published Semaglutide versus dulaglutide comparison
Source sentences
Summary
In comparison to Dulaglutide, Semaglutide displayed superior efficacy in reducing HbA1c levels (3.72; 95% CI: 0.02-7.41; p = 0.05) and FBS (2.66; 95% CI: 0.26-5.07; p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404509
10HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide showed superior efficacy to dulaglutide in reducing fasting blood sugar (printed comparative estimate 2.66,95% CI 0.26 to5.07;P=0.030); effect type/units were unstated and numbers retain the published semaglutide versus dulaglutide orientation.
In plain wordsIn reviewed clinical studies, semaglutide lowered fasting blood sugar more than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseFasting blood sugar
Study
n: not reported in source
Comparator
dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Printed comparative estimate
2.66
Semaglutide versus dulaglutide; effect type/units unstated, not inverted
95% CI
0.26 to 5.07
published Semaglutide versus dulaglutide orientation
P-value
0.03
published Semaglutide versus dulaglutide comparison
Source sentences
Summary
In comparison to Dulaglutide, Semaglutide displayed superior efficacy in reducing HbA1c levels (3.72; 95% CI: 0.02-7.41; p = 0.05) and FBS (2.66; 95% CI: 0.26-5.07; p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404510
11HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide and dulaglutide had no significant difference in weight change.
In plain wordsIn reviewed clinical studies, semaglutide and dulaglutide had no significant difference in weight change.
Peptide
Semaglutide
Outcome
No significant changeWeight change
Study
n: not reported in source
Comparator
dulaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no significant differences were found in weight and BMI change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404511
12HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide and dulaglutide had no significant difference in body mass index change.
In plain wordsIn reviewed clinical studies, semaglutide and dulaglutide had no significant difference in body mass index change.
Peptide
Semaglutide
Outcome
No significant changeBody mass index change
Study
n: not reported in source
Comparator
dulaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no significant differences were found in weight and BMI change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404512
13HumanSystematic reviewEfficacy outcome
Across included clinical studies, tirzepatide showed an advantage over semaglutide in reducing HbA1c (printed comparative estimate -0.45,95% CI -0.88 to-0.02;P=0.040); effect type/units were unstated and numbers retain the published tirzepatide versus semaglutide orientation.
In plain wordsIn reviewed clinical studies, tirzepatide lowered HbA1c more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Printed comparative estimate
−0.45
Tirzepatide versus semaglutide; effect type/units unstated, not inverted
95% CI
−0.88 to −0.02
published Tirzepatide versus semaglutide orientation
P-value
0.04
published Tirzepatide versus semaglutide comparison
Source sentences
Summary
Tirzepatide exhibited a notable advantage over Semaglutide in reducing HbA1c levels (-0.45; 95% CI: -0.88 to -0.02; p = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404513
14HumanSystematic reviewEfficacy outcome
Across included clinical studies, semaglutide had a smaller HbA1c reduction than tirzepatide (printed comparative estimate -0.45,95% CI -0.88 to-0.02;P=0.040); effect type/units were unstated and numbers retain the published tirzepatide versus semaglutide orientation.
In plain wordsIn reviewed clinical studies, semaglutide had a smaller HbA1c reduction than tirzepatide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c-reduction magnitude
Study
n: not reported in source
Comparator
tirzepatide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Printed comparative estimate
−0.45
Tirzepatide versus semaglutide; effect type/units unstated, not inverted
95% CI
−0.88 to −0.02
published Tirzepatide versus semaglutide orientation
P-value
0.04
published Tirzepatide versus semaglutide comparison
Source sentences
Summary
Tirzepatide exhibited a notable advantage over Semaglutide in reducing HbA1c levels (-0.45; 95% CI: -0.88 to -0.02; p = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404514
15HumanSystematic reviewEfficacy outcome
In reviewed clinical comparisons of tirzepatide and semaglutide, no clear tirzepatide superiority was observed for weight change; no signed estimate or semaglutide-superiority test was reported.
In plain wordsIn reviewed clinical studies, tirzepatide showed no clear weight change advantage over semaglutide; semaglutide superiority was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedWeight change
Study
n: not reported in source
Comparator
semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no clear superiority was observed for weight and FBS change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404515
16HumanSystematic reviewEfficacy outcome
In reviewed clinical comparisons of tirzepatide and semaglutide, no clear tirzepatide superiority was observed for weight change; no signed estimate or semaglutide-superiority test was reported.
In plain wordsIn reviewed clinical studies, tirzepatide showed no clear weight change advantage over semaglutide; semaglutide superiority was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedWeight change
Study
n: not reported in source
Comparator
tirzepatide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no clear superiority was observed for weight and FBS change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404516
17HumanSystematic reviewEfficacy outcome
In reviewed clinical comparisons of tirzepatide and semaglutide, no clear tirzepatide superiority was observed for fasting blood sugar change; no signed estimate or semaglutide-superiority test was reported.
In plain wordsIn reviewed clinical studies, tirzepatide showed no clear fasting blood sugar change advantage over semaglutide; semaglutide superiority was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedFasting blood sugar change
Study
n: not reported in source
Comparator
semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no clear superiority was observed for weight and FBS change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404517
18HumanSystematic reviewEfficacy outcome
In reviewed clinical comparisons of tirzepatide and semaglutide, no clear tirzepatide superiority was observed for fasting blood sugar change; no signed estimate or semaglutide-superiority test was reported.
In plain wordsIn reviewed clinical studies, tirzepatide showed no clear fasting blood sugar change advantage over semaglutide; semaglutide superiority was unstated.
Peptide
Semaglutide
Outcome
Direction not reportedFasting blood sugar change
Study
n: not reported in source
Comparator
tirzepatide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, no clear superiority was observed for weight and FBS change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
Show in the study text Report a problemFND-4044404518

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

19HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed clinical cohorts, the liraglutide-to-semaglutide sequence did not significantly affect HbA1c; the original comparison and native-drug-specific estimate were unstated.
In plain wordsIn reviewed clinical cohorts, switching from liraglutide to semaglutide did not significantly affect HbA1c; the comparison was unspecified.
Peptide
Semaglutide
Outcome
No significant changeHbA1c after transition from liraglutide
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Transitions from Liraglutide to Semaglutide did not significantly impact HbA1c levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4044404519
20HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed clinical cohorts after the liraglutide-to-semaglutide sequence, weight loss was observed (printed estimate 2.48,95% CI 0.45 to4.51;P=0.02); original reference/effect type/units and native-drug contribution were unstated.
In plain wordsIn reviewed clinical cohorts, the liraglutide-to-semaglutide sequence was linked to weight loss; the original comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseWeight loss after transition from liraglutide
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Printed sequence estimate
2.48
liraglutide-to-semaglutide sequence; original reference/effect units unstated
95% CI
0.45 to 4.51
sequence estimate
P-value
0.02
sequence outcome
Source sentences
Summary
However, weight loss (2.48; 95% CI: 0.45-4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55-20; p = 0.04) were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4044404520
21HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed clinical cohorts after the liraglutide-to-semaglutide sequence, fasting-glucose reduction was observed (printed estimate 10.76,95% CI 0.55 to20;P=0.04); original reference/effect type/units and native-drug contribution were unstated.
In plain wordsIn reviewed clinical cohorts, the liraglutide-to-semaglutide sequence was linked to fasting-glucose reduction; the original comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseFasting blood sugar after transition from liraglutide
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Printed sequence estimate
10.76
liraglutide-to-semaglutide sequence; original reference/effect units unstated
95% CI
0.55 to 20
sequence estimate
P-value
0.04
sequence outcome
Source sentences
Summary
However, weight loss (2.48; 95% CI: 0.45-4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55-20; p = 0.04) were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4044404521
22HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed clinical cohorts, the dulaglutide-to-semaglutide sequence did not significantly affect HbA1c; original comparison and native-drug contribution were unstated.
In plain wordsIn reviewed clinical cohorts, switching from dulaglutide to semaglutide did not significantly affect HbA1c; the comparison was unspecified.
Peptide
Semaglutide
Outcome
No significant changeHbA1c after transition from dulaglutide
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Transitioning from Dulaglutide to Semaglutide did not significantly affect HbA1c levels and weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4044404522
23HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In reviewed clinical cohorts, the dulaglutide-to-semaglutide sequence did not significantly affect weight change; original comparison and native-drug contribution were unstated.
In plain wordsIn reviewed clinical cohorts, switching from dulaglutide to semaglutide did not significantly affect weight change; the comparison was unspecified.
Peptide
Semaglutide
Outcome
No significant changeWeight change after transition from dulaglutide
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Transitioning from Dulaglutide to Semaglutide did not significantly affect HbA1c levels and weight change.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4044404523
24HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed clinical cohorts, the liraglutide-to-semaglutide sequence did not significantly affect HbA1c; the original comparison and native-drug-specific estimate were unstated.
In plain wordsIn reviewed clinical cohorts, switching from liraglutide to semaglutide did not significantly affect HbA1c; the comparison was unspecified.
Peptide
Liraglutide
Outcome
No significant changeHbA1c after liraglutide-to-semaglutide sequence
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Transitions from Liraglutide to Semaglutide did not significantly impact HbA1c levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4044404524
25HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed clinical cohorts after the liraglutide-to-semaglutide sequence, weight loss was observed (printed estimate 2.48,95% CI 0.45 to4.51;P=0.02); original reference/effect type/units and native-drug contribution were unstated.
In plain wordsIn reviewed clinical cohorts, the liraglutide-to-semaglutide sequence was linked to weight loss; the original comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseWeight loss after liraglutide-to-semaglutide sequence
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Printed sequence estimate
2.48
liraglutide-to-semaglutide sequence; original reference/effect units unstated
95% CI
0.45 to 4.51
sequence estimate
P-value
0.02
sequence outcome
Source sentences
Summary
However, weight loss (2.48; 95% CI: 0.45-4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55-20; p = 0.04) were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4044404525
26HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed clinical cohorts after the liraglutide-to-semaglutide sequence, fasting-glucose reduction was observed (printed estimate 10.76,95% CI 0.55 to20;P=0.04); original reference/effect type/units and native-drug contribution were unstated.
In plain wordsIn reviewed clinical cohorts, the liraglutide-to-semaglutide sequence was linked to fasting-glucose reduction; the original comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose after liraglutide-to-semaglutide sequence
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Printed sequence estimate
10.76
liraglutide-to-semaglutide sequence; original reference/effect units unstated
95% CI
0.55 to 20
sequence estimate
P-value
0.04
sequence outcome
Source sentences
Summary
However, weight loss (2.48; 95% CI: 0.45-4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55-20; p = 0.04) were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Scopus, Cochrane Library, Google Scholar, and Web of Science (ClinicalTrials.gov for unpublished records) from their inception to 5 February 2025, including observational cohort studies and randomized controlled trials.
Summary · context
The meta-analysis comprised 16 studies and 5,997 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4044404526

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.

Summary

Results from this study26

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

Keywords